Abstract
5-Fluorouracil (5-FU) is one of the few anticancer agents that has been developed on a rational basis [10]. Although it has been clinically used since the late 1950s, 5-FU has recently attracted new interest because of two developments:
-
1.
Methods have been developed which allow the detection of small amounts of 5-FU and most of its metabolites.
-
2.
There has been a revival of regional drug administration, especially hepatic artery infusion. Since 5-FU is metabolized in the liver to a significant degree, it is one of the drugs used for this administration.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bertino JR, Sawicki WL, Lindquist CA, Gupta VS (1977) Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res 37: 327–328
Blumenreich MS, Woodcock TM, Allegra M, Richman SP, Kubota TT, Allegra IC (1982) Sequential therapy with methotrexate and 5-fluorouracil for adenocarcinoma of the colon. Proc Am Soc Clin Oncol 18: 102 (Abstr)
Burnet R, Smith FP, Hoerni B, Lagarde C, Schein P (1981) Sequential methotrexate-5-fluorouracil in advanced measurable colorectal cancer: lack of appreciable therapeutic synergism. Proc Am Soc Clin Oncol 17: 370 (Abstr)
Cadman E, Heimer R, Benz C (1981) The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells. J Biol Chem 256: 1695–1704
Cantell JE, Burnet R, Lagarde C, Schein PS, Smith FP (1982) Phase II study of sequential methotrexate-5-FU therapy in advanced measurable colorectal cancer. Cancer Treat Rep 66: 1563–1565
Carrico CK, Glazer RI (1979) Effect of 5-fluorouracil on the synthesis and translation of polyadenylic acid-containing RNA from regenerating rat liver. Cancer Res 39: 3694–3701
Coates AS, Hedley D, Fox RM, Raghavan D, Tattersall MHN (1983) Randomised trial of sequential methotrexate (M) followed by 5-fluorouracil (F) versus F followed by M. Proc Am Assoc Cancer Res 74: 140 (Abstr)
Fernandes DJ, Bertino JR (1980) 5-fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyuridylate binding to thymidylate synthetase by dihydropteroyl-polyglutamates. Proc Natl Acad Sci USA 77: 5663–5667
Hartman KU, Heidelberger C (1961) Studies on fluorinated pyrimidines. VIII. Inhibition of thymidylate synthetase. J Biol Chem 236: 3006–3013
Heidelberger C, Chandhuri NK, Danenberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer J, Pleven E, Scheiner J (1957) Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 179: 663–666
Herrmann R, Spehn J, Beyer JH, von Franque U, Schmieder A, Holzmann K, Abel U (1984a) Sequential methotrexate and 5-fluorouracil. Improved response rate in metastatic clorectal cancer. J Clin Oncol 2: 591–594
Herrmann R, Manegold C, Schroeder M, Tigges FJ, Bartsch H, Jungi F, Fritze D (1984b) Sequential methotrexate and 5-fluorouracil in breast cancer resistant to the conventional application of these drugs. Cancer Treat Rep 68: 1279–1281
Herrmann R, Kunz W, Osswald H, Ritter M, Port RD (1985) The effect of methotrexate pretreatment on 5-fluorouracil kinetics in sarcoma 180 in vivo. Eur J Cancer Clin Oncol 21: 753–758
Kufe DW, Egan EM (1981) Enhancement of 5-fluorouracil incorporation into human lymphoblast ribonucleic acid. Biochem Pharmacol 30: 129–133
Panasci L, Margolese R (1982) Sequential methotrexate and 5-fluorouracil in breast and colorectal cancer. Results of increasing the dose of FU. Proc Am Soc Clin Oncol 18: 101 (Abstr)
Piper AA, Nott SE, Mackinnon WB, Tattersall MHN (1983) Critical modulation by thymidine and hypoxanthine of sequential methotrexate-5-fluorouracil synergism in murine L1210 cells. Cancer Res 43: 5701–5705
Wayss K, Herrmann R, Mattem J, Volm M (1985) Sequential methotrexate and 5-fluorouracil in human tumor xenografts. Med Oncol Tumor Pharmacother 2 (1): 27–32
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Herrmann, R. (1986). Enhancement of the Effects of 5-Fluorouracil. In: Herfarth, C., Schlag, P., Hohenberger, P. (eds) Therapeutic Strategies in Primary and Metastatic Liver Cancer. Recent Results in Cancer Research, vol 100. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-82635-1_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-82635-1_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-82637-5
Online ISBN: 978-3-642-82635-1
eBook Packages: Springer Book Archive